Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Forbes
created a customized gene editing therapy to correct KJ's rare genetic mutation, which made his body unable to properly process protein. Without this personalized treatment, his future looked bleak: the possibility of progressive brain damage due to high ammonia levels his body could not remove. But after three infusions containing billions of gene editors delivered to his liver to correct the mutation, today baby KJ appears to be doing well and developing normally. At a conference last month hosted by STAT News, the adorably plump boy squirmed in a tiny tuxedo. I recently had the privilege of speaking to one of key scientists behind this breakthrough: Dr. David Liu of the Broad Institute, whose lab is credited with developing both prime editing and base editing, which is the technology used to treat baby KJ. In an hour-long interview, Liu offered insights on this hopeful time in medical history, the scientific frontiers he and his colleagues continue to push, and the bottlenecks
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]Seeking Alpha
- Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) had its "speculative buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- 11/4/25 - Form 8-K
- BEAM's page on the SEC website